Biotech / MedTech

Geb Impact is one of the finalists of Fund at first pitch at BEYOND Expo 2024.

#AI allows humans to conduct research and achieve innovation in a more efficient, more cost-effective, and more systematic way. However, looking back at the history of human inventions, some of the most representative inventions stem not only from systematic research but also from human curiosity, keen observation, and serendipity.

Engineering biology is expected to disrupt all industries, as all organizations surveyed in Singapore believe biosolutions will create a major disruption in their industry in the next ten years, Capgemini Research Institute said in a report on Monday.

Singapore-based biotech firm Chitose Bio Evolution Pte. Ltd. has announced the issuance of new shares of JPY 1 billion ($6.2 million) through a third-party allotment to Sumitomo Mitsui Banking Corporation (SMBC).

Singapore-based healthcare-dedicated asset management firm CBC Group announced that its controlled portfolio company, Hasten Biopharmaceutical (Hasten), an innovation-driven biopharmaceutical company, has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a South Korean biopharmaceutical…

HSBC has levelled up its strategic partnership with Gene Solutions, a biotechnology company based in Vietnam, through a social loan which allows the firm to continue expanding its healthcare services to Vietnam and ASEAN’s citizens.

Singapore state-owned investor Temasek has led EUR 188 million ($208 million) equity investment in German radiopharmaceutical biotech firm ITM Isotope Technologies Munich SE (ITM).

Allozymes, a Singapore-based innovator in enzyme discovery and engineering, has on Monday announced the closing of a $15 million Series A funding round led by Seventure Partners of France and Xora Innovation of Singapore.

NSG BioLabs, Singapore's largest provider of biotech co-working laboratory and office space, has successfully concluded a $14.5 million financing round. The round was led by Celadon Partners, an Asian private equity firm.

As we peer into the future of the APAC biotech landscape, biotech startups will continue to see opportunities for innovation and funding on the horizon. The anticipated trends in strategic investments, government support, and collaborative efforts suggest that 2024 will be a pivotal year for aspiring biotech entrepreneurs. Success in this dynamic landscape…